Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
Date:8/19/2009

SEATTLE, Aug. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.

In connection with the offering, the investor received warrants to purchase up to 4,713,276 shares of common stock. The warrants have an exercise price of $1.70 per warrant share, for total potential additional proceeds to the Company of approximately $8.0 million upon exercise of the warrants. The warrants are exercisable immediately upon issuance and terminate nine months after the date of issuance.

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications, and general working capital.

Shares of the Series 2 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting rights on general corporate matters.

The closing of the offering is expected to occur on August 24, 2009, at which time the Company will receive the cash proceeds and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
2. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
5. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
6. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
7. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
10. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
11. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/27/2015)... BERKELEY, Calif. , Feb. 27, 2015  Steep ... in the US and internationally, intends to open a ... Albuquerque, New Mexico , bringing advanced scientific ... of cannabis. Steep Hill is currently the ... Health to conduct potency and contaminant testing in order ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... In this month,s special issue of Physics World, which examines ... Kinsler of Imperial College London describe a new type of ... events. Using the ultimate bank heist as an example, ... use an "event cloak" to steal money from a safe, ...
... looked like when it was a baby. They know what ... it looked in its youth. Thanks to technological advances, however, ... picture of how the cosmos developed into the kind of ... They plan to gather these never-before-obtained insights with a ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... on-label use of PROVENGE® (sipuleucel-T), the first autologous ... minimally symptomatic metastatic castrate resistant (hormone refractory) prostate ... U.S. Food and Drug Administration (FDA) approved the ...
Cached Biology Technology:Why 'event cloaks' could be the key to the ultimate bank heist 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 3Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 4Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 3Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 4
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... CHAMPAIGN, lll. Blood clotting is a complicated business, ... to injury. In a new study, researchers report that they ... interaction that is vital to blood clotting. This interaction ... baffled scientists for decades. The study appears ...
... Research from North Carolina State University shows that ... good in landfills, because they are releasing a powerful ... such as disposable cups and utensils, are broken down ... Dr. Morton Barlaz, co-author of a paper describing the ...
... lightweight web service interface for accessing massive amounts ... and private domains has been developed by researchers ... powerful RIKEN Scientists, Networking System (SciNetS), the service ... to millions of data records and their network ...
Cached Biology News:Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3Study: Biodegradable products may be bad for the environment 2Web interface defines new paradigm for life science data-sharing 2
Request Info...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Request Info...
Request Info...
Biology Products: